Cancer Home > Ponatinib

People who have leukemia may benefit from taking ponatinib. By interrupting the production of abnormal blood cells, this prescription medication can help slow down the progression of the cancer. It is specifically approved to treat certain types of leukemia when other forms of treatment fail. Ponatinib comes as a tablet that is taken once a day.


What Is Ponatinib?

Ponatinib (Iclusig®) is a prescription medication approved for the treatment of leukemia, which is cancer of the blood cells and bone marrow. It is specifically approved to treat the following types of leukemia:
  • Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)
  • Chronic myeloid leukemia (CML).
Ponatinib is reserved for use in people who no longer benefit from, or who cannot tolerate, certain other types of treatment.
(Click What Is Ponatinib Used For? for more information on this topic, including possible off-label uses.)

Are There Side Effects?

Just like any medicine, ponatinib can cause side effects. Although not everyone who takes the drug will have problems, most people will experience some type of side effect during treatment. Talk with your healthcare provider about ways to prevent or lessen reactions to this drug.
Common side effects of ponatinib include but are not limited to:
(Click Ponatinib Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider.)
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation




Related Channels

eMedTV Links
Copyright © 2006-2021 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.